Response to: McBride A, Campbell K, Bikkina M, et al. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. J Med Econ 2017;20:1083-93
| Autor: | Jon Campbell, Mark Bensink, Charles Bowers, Christine Edwards |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Oncology
medicine.medical_specialty Filgrastim business.industry Health Policy Chemotherapy-Induced Febrile Neutropenia Filgrastim-sndz food and beverages Biosimilar Antineoplastic Agents Polyethylene Glycols 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine medicine Humans 030212 general & internal medicine business Biosimilar Pharmaceuticals Pegfilgrastim medicine.drug |
| Zdroj: | Journal of medical economics. 21(6) |
| ISSN: | 1941-837X |
| Popis: | McBride et al.1 recently published what was referred to as “cost-efficiency analyses”. The analyses completed by the authors compared four alternative granulocyte colony-stimulating factor (G-CSF) ... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|